TRANSDERM Drug Patent Profile

Which patents cover Transderm, and when can generic versions of Transderm launch?

Transderm is a drug marketed by Baxter Hlthcare Corp and Novartis and is included in two NDAs.

The generic ingredient in TRANSDERM is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Transderm

A generic version of TRANSDERM was approved as nitroglycerin by AM REGENT on May 24^th, 1988.

Summary for TRANSDERM

US Patents:	0
Applicants:	2
NDAs:	2
Drug Prices:	Drug price information for TRANSDERM
DailyMed Link:	TRANSDERM at DailyMed

See drug prices for TRANSDERM

US Patents and Regulatory Information for TRANSDERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-003	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-002	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-005	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996		DISCN	Yes	No